Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.

Emmanuel S. Antonarakis,Hao Wang,Benjamin A. Teply,William Kevin Kelly,Jamie Willms,Rana Sullivan,Serina King,Catherine Handy Marshall,Tamara L. Lotan

Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.

2019

Emmanuel S. Antonarakis
Hao Wang
Benjamin A. Teply
William Kevin Kelly
Jamie Willms
Rana Sullivan
Serina King
Catherine Handy Marshall
Tamara L. Lotan

5045Background: Pts with biochemically-recurrent (BCR) prostate cancer after local therapy with a PSA doubling time (PSADT) of ≤6 mo are likely to develop metastases and death from their disease. W...

Keywords:

Recurrent prostate cancer
Interim
Prostatectomy
Phases of clinical research
Olaparib
Oncology
Biomarker Analysis
Pathology
Medicine
Internal medicine
Disease
Doubling time
breakpoint cluster region
Prostate cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations